The United States agrees to the first blood test to detect Alzheimer’s disease
probability Discover Alzheimer’s Through the blood sample is already a reality. At least, in the United States, where the Food and Food Administration (FDA) has just agreed to the first blood test to detect Alzheimer’s disease, LumiPulse G Ptau217/ß-andDamloid 1-42 Plasma Diagnostics, Inc.
As with all diseases, early on Alzheimer’s disease The best is to diagnose the patient. In this specified case, although we do not have a final treatment for the condition of treating treatments that reduce symptoms and slow down the development of pathology, so it is easy to understand the importance of developing simple and low -gas diagnostic techniques such as these blood tests.
How to work
In fact, it is found in panorama research A kind of profession among scientists all over the world to develop the methods of this chapterWhere the Food and Drug Administration license (under the category of “innovative”) represents a basic milestone.
As the Foundation’s details, Lumipulse testing measures The amount of two proteins in the blood plasma: Ptau 217 and Beta-Ayloid 1-42. These are one of the variable proteins that accumulate in brain tissue for people with Alzheimer’s disease as a distinctive feature of the disease. In this way, through the concentration of plasma, it is possible to determine the presence or absence of shells and panels (the name that the accumulation of these two protein, respectively) in the brain.
To date, the main Laboratory diagnosis test For Alzheimer’s disease, in analyzing a sample of the patient’s brain fluid, which was obtained by the lumbar hole. This method was expensive and gas, which hindered access to patients.
An important step, but not final
As part of the FDA approval, it should be noted that the test can Shipping both positive and false results. Therefore, it is not likely that it is not currently a final and unique tool in the United States, but its biggest capabilities are immediately the use of pre -written patients participating in clinical trials.
In the medium term, it may be implemented by Primary care suppliers In people with symptoms or with important risk factors, patients who appear a positive result become examined by a neurologist in more accurate ways.
At the same time, it should also be borne in mind that the requirements for approval of this type of diagnostic methods differ in the United States and in the European Union, which explains this The Lumipulse test has not been used In this last region. We will have to wait to reach clinical practice on our continent and know how its concrete use will be implemented.
Reference
FDA (2025). The Food and Drug Administration scanns the first blood test used in diagnosing Alzheimer’s disease. It was consulted online https://www.fda.gov/news-evenks/press-anicomens/fda-clears-firstt-lood-test-jgnosis-alzeimers-disease May 26, 2025.
We are already on WhatsApp! If you want to get all the current news and the most important news today, Click here and join our channel. It is a free, comfortable and safe system.
